Candel Therapeutics (CADL) EBITDA Yield: History & Chart

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T21:25:57.385Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:25:57.385Z.

Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -71,162,000
Quote market capitalization: 723,176,874
Total debt · period ending 2026-06-30: 49,517,000
Cash · period ending 2026-06-30: 201,565,000

FMP input reference: 370e13d786cc28e63fbc6719e554b7ac483294971c86eef7c80c09e39811c756

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

CADL EBITDA Yield Metrics

EBITDA YIELD

N/A

CADL Competitors' EBITDA Yield

CADL

Candel Therapeutics, Inc.

Current

Market Cap

$723.18M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACHV

Achieve Life Sciences, Inc.

vs CADL

Market Cap

$721.69M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AVTX

Avalo Therapeutics, Inc.

vs CADL

Market Cap

$714.37M

EBITDA Yield

N/A

TTM Avg

4.15%

3Y Avg

4.09%

5Y Avg

4.09%

COLL

Collegium Pharmaceutical, Inc.

vs CADL

Market Cap

$709.65M

EBITDA Yield

35.15%

TTM Avg

23.06%

3Y Avg

19.27%

5Y Avg

16.31%

APMD

Apnimed, Inc.

vs CADL

Market Cap

$742.70M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AVBP

ArriVent BioPharma, Inc.

vs CADL

Market Cap

$702.82M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DSGN

Design Therapeutics, Inc.

vs CADL

Market Cap

$747.61M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CTKB

Cytek Biosciences, Inc.

vs CADL

Market Cap

$694.79M

EBITDA Yield

N/A

TTM Avg

0.40%

3Y Avg

0.67%

5Y Avg

0.67%

WVE

Wave Life Sciences Ltd.

vs CADL

Market Cap

$693.61M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ATTO

Attovia Therapeutics, Inc.

vs CADL

Market Cap

$753.02M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Candel Therapeutics, Inc. (CADL)	$723.18M	N/A	N/A	N/A	N/A
Achieve Life Sciences, Inc. (ACHV)vs ›	$721.69M	N/A	N/A	N/A	N/A
Avalo Therapeutics, Inc. (AVTX)vs ›	$714.37M	N/A	4.15%	4.09%	4.09%
Collegium Pharmaceutical, Inc. (COLL)vs ›	$709.65M	35.15%	23.06%	19.27%	16.31%
Apnimed, Inc. (APMD)vs ›	$742.70M	N/A	N/A	N/A	N/A
ArriVent BioPharma, Inc. (AVBP)vs ›	$702.82M	N/A	N/A	N/A	N/A
Design Therapeutics, Inc. (DSGN)vs ›	$747.61M	N/A	N/A	N/A	N/A
Cytek Biosciences, Inc. (CTKB)vs ›	$694.79M	N/A	0.40%	0.67%	0.67%
Wave Life Sciences Ltd. (WVE)vs ›	$693.61M	N/A	N/A	N/A	N/A
Attovia Therapeutics, Inc. (ATTO)vs ›	$753.02M	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

CADL EBITDA Yield Metrics

CADL Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics